卡瑞利珠单抗和阿帕替尼联合放疗对晚期寡转移非小细胞肺癌有效。
Camrelizumab and Apatinib Combined with Radiotherapy Is Effective in Advanced Oligometastatic Non-Small-Cell Lung Cancer.
作者信息
Ye Wei, Song Zhonghua, Lin Zhongkun
机构信息
Respiratory Medicine, Shandong Provincial Third Hospital, Jinan 250031, Shandong, China.
Department of General Practice, Shandong Provincial Third Hospital, Jinan 250031, Shandong, China.
出版信息
Evid Based Complement Alternat Med. 2022 Sep 24;2022:5067402. doi: 10.1155/2022/5067402. eCollection 2022.
OBJECTIVE
To investigate the effect of camrelizumab + apatinib combined with radiotherapy on the expression of TRIM27, SCC-Ag, and CYFRA21-1 in advanced oligometastatic non-small-cell lung cancer (NSCLC).
METHODS
A retrospective analysis of patients with oligometastatic NSCLC who were treated at our hospital from January 1, 2021, to March 31, 2022. Patients who met the inclusion criteria were summarized into an observation group (camrelizumab on the basis of the control group), or a control group (radiotherapy combined with oral apatinib). The disease control rate, immune function, changes in the levels of TRIM27, SCC-Ag, CYFRA21-1, and the occurrence of adverse effects were compared between the two groups.
RESULT
There were 86 patients who met the inclusion criteria, with 53 cases in the observation group and 33 cases in the control group. There were significant differences in complete remission (CR, 25/53 vs. 10/33), partial remission (PR, 17/53 vs. 12/33), disease control (DC, 7/53 vs. 4/33), disease progression (DP, 4/53 vs. 7/33), and disease control rate (49/53 vs. 26/33) between the observation group and the control group. There was no significant difference in immune function between the two groups before treatment ( > 0.05). After treatment, the levels of CD3, CD4, CD4/CD8 cells, and NK cells in the observation group were higher (=0.015, 0.035, 0.003, 0.001, respectively), while the level of CD8 cells was lower ( < 0.001). There were no significant differences in TRIM27, SCC-Ag, or CYFRA21-1 between the two groups before treatment ( > 0.05). After treatment, the observation group had lower levels of TRIM27 (=0.035), SCC-Ag (=0.045), and CYFRA21-1 (=0.003). There was no significant difference in the occurrence of adverse events between the two groups ( < 0.05).
CONCLUSION
Treatment of camrelizumab + apatinib combined with radiotherapy is effective for advanced oligometastatic NSCLC, with mild adverse effects.
目的
探讨卡瑞利珠单抗+阿帕替尼联合放疗对晚期寡转移非小细胞肺癌（NSCLC）中TRIM27、鳞状细胞癌抗原（SCC-Ag）和细胞角蛋白19片段（CYFRA21-1）表达的影响。
方法
回顾性分析2021年1月1日至2022年3月31日在我院接受治疗的寡转移NSCLC患者。符合纳入标准的患者被纳入观察组（在对照组基础上加用卡瑞利珠单抗）或对照组（放疗联合口服阿帕替尼）。比较两组的疾病控制率、免疫功能、TRIM27、SCC-Ag、CYFRA21-1水平变化及不良反应发生情况。
结果
符合纳入标准的患者有86例，其中观察组53例，对照组33例。观察组与对照组在完全缓解（CR，25/53 vs. 10/33）、部分缓解（PR，17/53 vs. 12/33）、疾病控制（DC，7/53 vs. 4/33）、疾病进展（DP，4/53 vs. 7/33）和疾病控制率（49/53 vs. 26/33）方面存在显著差异。两组治疗前免疫功能无显著差异（>0.05）。治疗后，观察组CD3、CD4、CD4/CD8细胞及自然杀伤（NK）细胞水平较高（分别为=0.015、0.035、0.003、0.001），而CD8细胞水平较低（<0.001）。两组治疗前TRIM27、SCC-Ag或CYFRA21-1无显著差异（>0.05）。治疗后，观察组TRIM27（=0.035）、SCC-Ag（=0.045）和CYFRA21-1（=0.003）水平较低。两组不良反应发生情况无显著差异（<0.05）。
结论
卡瑞利珠单抗+阿帕替尼联合放疗治疗晚期寡转移NSCLC有效，且不良反应轻微。
Zotero 插件